Chimerix Inc (CMRX)

• $0.85

  $0.89

  $0.88
  

  3.17%

  Downside

  Day's Volatility :4.49%

  Upside

  1.37%

  
• $0.75

  $1.30

  $0.88
  

  14.77%

  Downside

  52 Weeks Volatility :42.31%

  Upside

  32.31%

  

Returns

What analysts predicted

Upside of 676.14%

• RA Capital Management, LLC

  9.82%

• Monaco Asset Management

  4.88%

• Vanguard Group Inc

  4.85%

• Armistice Capital, LLC

  2.48%

• Acadian Asset Management LLC

  2.43%

• Renaissance Technologies Corp

  2.07%

led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed